MedTecX (https://www.medtecx.com/en/) is a global medical technology company driven by unmet clinical needs in chronic diseases such as urology, gastroenterology, and respiratory. Our mission is to accelerate access to the best value medical technologies to every patient, around the world.  

MedTecX has established R&D centers and manufacturing facilities in Shanghai, Suzhou and San Francisco. Since its founding in 2018, the company has been continuously developing next-generation technologies, including:
- Advanced minimally invasive therapies (MIST) to treat benign prostatic hyperplasia (BPH) for safe procedures and effective long term results 
- Personalized non-invasive and minimally invasive therapies for stress incontinence (SUI) and overactive bladder (OAB) for individualized management at hospitals and home
- Intelligent stone management system, including continuous irrigation and aspiration system, for more efficient and residual-free stone clearance 

Currently, the company has over 10 products in development and clinical research stages. Starting from 2023, MedTecX has commercialized over 20 products in the China market, successively obtaining CE/FDA certifications and beginning to launch in oversea markets in 2025. 

MedTecX

Org chart

Teams

Offices

MedTecX

Org chart

Teams

Offices

Related companies